Exosens SA

As of June 30, 2026, Exosens SA carries a market capitalization of 2.86B, placing it among publicly traded companies globally. Its enterprise value stands at 3.06B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Exosens SA's next confirmed earnings release is scheduled for February 22, 2027.

As of June 30, 2026, Exosens SA has 50.91M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Exosens SA maintains a current ratio of 2.35, meaning it holds 2.4x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

As of the close on August 11, 2026, Exosens SA's stock has gained approximately 50.65% over the past 52 weeks. The 50-day moving average sits at 49.21, while the 200-day moving average is 29.42.

As of June 30, 2026, Exosens SA holds 69.23M in cash and equivalents against 264.89M in total debt, resulting in a net debt position of 178.33M. Total book value stands at 450.88M, with working capital of 175.79M providing operational flexibility.